

	Pfizer	Moderna
Diluent	0.9% Sodium Chloride (preservative-free NS)	N/A
Ages indicated (yrs)	≥ 16	≥ 18
Dosing Schedule	2 dose series separated by 21 days	2 dose series separated by 28 days
Early/Late Second Doses	Second doses administered within a grace period of ≤4 days from the recommended date for the second dose are considered valid; however, doses administered earlier do not need to be repeated. The second dose should be administered as close to the recommended interval as possible. <b>However, there is no maximum interval between the first and second dose for either vaccine.</b>	
Storage: Frozen or Ultra-Cold	<ul style="list-style-type: none"> <li>Store in freezer between -80°C to -60°C</li> <li>Protect from light until ready to use</li> </ul>	<ul style="list-style-type: none"> <li>Stored at -20°C for up to 6 months</li> </ul>
Storage of unpunctured, undiluted, vials:	<ul style="list-style-type: none"> <li>Refrigerated (2°C to 8°C): Up to 5 days</li> <li>Room Temperature: 2 hours</li> </ul>	<ul style="list-style-type: none"> <li>Refrigerated (2°C to 8°C): 30 days</li> <li>Room Temperature: 12 hours</li> </ul>
Storage of punctured Vials	<ul style="list-style-type: none"> <li>Store at room temperature and use within 6 hours from the time of dilution (discard remainder after 6 hours).</li> <li>Minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.</li> <li>Do not refreeze.</li> </ul>	<ul style="list-style-type: none"> <li>6 hours</li> </ul>
Preparation	<ul style="list-style-type: none"> <li>Thaw vials for 30 minutes and allow to reach room temperature before dilution.</li> <li>Reconstitute with 1.8 mLs NS</li> </ul>	None
Dose	0.3 mLs	0.5 mLs
Doses per vial	5	10
Administration Site	IM	
Efficacy	Post-1 <sup>st</sup> dose: 52% Post-completed series: 95%	Post-completed series: 94.1%
Adverse Reactions	Injection site reaction 84.1% Fatigue 62.9% Headache 55.1% Muscle pain 38.3% Chills 31.9% Joint pain 23.6% Fever 14.2%	Injection site pain: 92.0% Fatigue 70.0% Headache 64.7% Myalgia 61.5% Arthralgia 46.4% Chills 45.4% Nausea/vomiting 23.0% Axillary swelling/tenderness 19.8% Fever 15.5% Swelling at the injection site 14.7% Erythema at the injection site 10.0%
Ingredients	mRNA, lipids, potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dehydrate, and sucrose.	mRNA, lipids, tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.

Frequently Asked Questions:	
Interchangeable for subsequent doses?	No
FDA approval?	No (EUA only)
Co-administration with other vaccines?	Administer COVID-19 vaccine alone, with a minimum interval of 14 days prior to or post additional immunization.
Previous treatment with COVID antibody therapy?	Defer vaccination for at least 90 days to avoid vaccine-induced immune responses.
Vaccinations in setting of exposure?	Defer until quarantine period is completed.
Vaccinations in setting of infection?	Defer if active acute illness; previous infection is not a contraindication.
Can you take the vaccine if you have underlying medical conditions?	<ul style="list-style-type: none"> <li><b>Immunocompromised individuals</b> may still receive COVID-19 vaccination if they have no contraindications to vaccination. However, they should be counseled about the unknown vaccine safety profile and effectiveness (potentially reduced), as well as the potential for reduced immune responses and the need to continue to follow all current guidance to protect themselves against COVID-19.</li> <li>Persons with <b>autoimmune conditions</b> who have no contraindications to vaccination may receive an mRNA COVID-19 vaccine.</li> </ul>
Pregnancy/lactation data?	<ul style="list-style-type: none"> <li>Limited data; conversation with provider is strongly encouraged.</li> <li>Likely not a risk to a breastfed infant.</li> </ul>

Resources: <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html> and <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>